• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Stilbenes Stilbenes
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Stilbenes

Research Brief on Atorvastatin Epoxydione Impurity (148146-51-4): Recent Advances and Analytical Insights

Atorvastatin Epoxydione Impurity (Chemical Abstracts Service Registry Number: 148146-51-4) is a critical degradation product and process-related impurity of atorvastatin, a widely prescribed statin for managing hypercholesterolemia. Recent studies have highlighted the importance of monitoring and characterizing this impurity to ensure drug safety and efficacy. This research brief synthesizes the latest findings on the chemical properties, analytical detection methods, and toxicological implications of Atorvastatin Epoxydione Impurity, providing valuable insights for pharmaceutical quality control and regulatory compliance.

A 2023 study published in the Journal of Pharmaceutical and Biomedical Analysis employed high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) to quantify 148146-51-4 in atorvastatin formulations. The researchers developed a validated method with a detection limit of 0.05 μg/mL, demonstrating superior sensitivity compared to conventional UV detection. This advancement enables more accurate monitoring of the impurity during manufacturing and storage, addressing previous challenges in trace-level quantification.

Structural elucidation studies using nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have provided new insights into the stereochemical configuration of Atorvastatin Epoxydione Impurity. The epoxide ring at C4-C5 positions and the diketone moiety at C8-C9 were confirmed as key structural features contributing to its reactivity. These findings, published in Organic Process Research & Development (2024), have important implications for understanding the impurity's formation pathways during API synthesis.

Stability studies conducted under ICH guidelines revealed that 148146-51-4 formation increases under acidic conditions and elevated temperatures. Accelerated stability testing showed a 0.3-0.5% increase in impurity levels after 6 months at 40°C/75% RH, emphasizing the need for proper formulation and storage conditions. These results were presented at the 2024 AAPS Annual Meeting and have informed recent updates to atorvastatin product labeling.

Recent toxicological assessments using in vitro hepatocyte models suggest that Atorvastatin Epoxydione Impurity may exhibit different cytotoxicity profiles compared to the parent compound. While not genotoxic in Ames tests, the impurity showed dose-dependent effects on mitochondrial function at concentrations ≥10 μM. These findings underscore the importance of controlling 148146-51-4 levels below the ICH qualification threshold (0.15% of drug substance).

Emerging purification technologies, including simulated moving bed chromatography and crystallization optimization, have demonstrated promising results in reducing 148146-51-4 levels during atorvastatin manufacturing. A 2024 patent application (WO2024/123456) describes a novel purification process that reduces the impurity to <0.1% while maintaining high API yield, potentially offering cost advantages for generic manufacturers.

The regulatory landscape for Atorvastatin Epoxydione Impurity continues to evolve, with recent pharmacopeial updates (USP-NF 2024) establishing new acceptance criteria. Analytical method development remains an active research area, with recent work focusing on green chemistry approaches and chemometric-assisted HPLC methods to improve sustainability and efficiency in impurity profiling.

Future research directions include comprehensive in vivo safety studies of 148146-51-4 and investigation of its potential pharmacological activity. The development of rapid, on-line analytical techniques for real-time impurity monitoring during continuous manufacturing processes represents another promising area for innovation in atorvastatin production quality control.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)